Equities

Lee's Pharmaceutical Holdings Ltd

Lee's Pharmaceutical Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.22
  • Today's Change-0.01 / -0.81%
  • Shares traded117.00k
  • 1 Year change+1.67%
  • Beta0.6949
Data delayed at least 15 minutes, as of Nov 22 2024 07:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

  • Revenue in HKD (TTM)1.20bn
  • Net income in HKD63.06m
  • Incorporated2001
  • Employees993.00
  • Location
    Lee's Pharmaceutical Holdings LtdUnit 110-111, Bio-Inf. Centre,No.2 Science Park West Avenue,Hong Kong Science Park, Shatin Hong KongHKG
  • Phone+852 23141282
  • Fax+852 23141708
  • Websitehttps://www.leespharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Uni-Bio Science Group Ltd508.40m98.86m382.14m458.003.901.223.210.75170.01590.01590.08120.05071.272.2312.211,249,140.0024.761.4632.971.9783.5180.5919.441.232.17168.550.22670.0010.0829.0884.04--84.98--
Tianda Pharmaceuticals Ltd384.68m-47.26m387.01m695.00--0.7107--1.01-0.022-0.0220.17890.25330.43412.974.46445,745.10-5.34---7.97--45.83---12.30--0.6748-9.510.1536--------------
3D Medicines Inc525.09m-483.09m521.58m193.00--0.5727--0.9933-2.05-2.052.203.530.37464.945.792,651,946.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Fusen Pharmaceutical Co Ltd457.06m-96.33m665.37m1.14k--1.21--1.46-0.1292-0.12920.61360.74550.32121.685.01398,137.50-6.770.9678-13.961.7453.1851.95-21.082.590.526-2.100.403127.9515.024.13-4.83--0.2124--
Lee's Pharmaceutical Holdings Ltd1.20bn63.06m724.27m993.0011.490.42273.690.6040.10710.10712.042.910.44032.119.701,134,410.001.9813.332.5217.7651.4961.924.5036.200.74256.580.1323.59-14.61-1.53-67.44-47.49-12.19-31.34
Zhaoke Ophthalmology Ltd61.46m-243.91m742.75m297.00--0.3401--12.09-0.4478-0.44780.11284.000.02331.2516.09196,357.80-9.23---10.51--82.03---396.86--5.48-24.020.1114------5.47------
Pak Fah Yeow International Ltd265.21m96.45m760.40m101.007.891.017.332.870.30940.30940.85072.410.28692.8423.532,600,118.0010.443.9911.324.1887.0580.7936.3721.274.225.260.0055100.6876.0612.94250.6623.0218.83-8.06
Zhongzhi Pharmaceutical Holdings Ltd2.20bn119.57m777.24m2.74k6.370.65383.360.3540.14120.14122.591.381.092.687.39830,705.705.997.699.1711.7557.5560.445.496.730.9033213.590.151642.4612.2612.4153.0013.8617.65--
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd901.25m184.38m789.95m678.004.280.46416.380.87650.32910.32911.613.040.35742.102.941,062,796.007.317.6710.2510.4875.4678.7920.4620.681.62--0.05027.22-0.00495.38-23.43-1.67-1.14--
Hbm Holdings Ltd562.02m165.78m979.73m158.005.680.98335.001.740.22530.22530.76231.300.32583.9616.673,175,272.009.59-54.6113.25-66.0495.5797.8129.42-400.283.448.140.3502--120.13127.06116.61---12.62--
Data as of Nov 22 2024. Currency figures normalised to Lee's Pharmaceutical Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.10%Per cent of shares held by top holders
HolderShares% Held
UBS Switzerland AG (Investment Management)as of 14 Oct 202429.33m4.98%
Fidelity Management & Research Co. LLCas of 20 Feb 202329.20m4.96%
Dimensional Fund Advisors LPas of 07 Nov 20246.06m1.03%
Dimensional Fund Advisors Ltd.as of 31 Aug 2024277.97k0.05%
Acadian Asset Management LLCas of 30 Sep 2024127.35k0.02%
Carne Global Fund Managers (Ireland) Ltd.as of 31 Mar 2023112.06k0.02%
Mercer Global Investments Europe Ltd.as of 30 Jun 202395.00k0.02%
Lazard Asset Management LLCas of 31 Oct 202486.11k0.02%
FIL Investments Internationalas of 30 Jun 202450.00k0.01%
Victory Capital Management, Inc. (Investment Management)as of 30 Jun 202445.55k0.01%
More ▼
Data from 28 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.